Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?

Author(s): Chewki Ziani-Cherif, Bachir Mostefa-Kara and Fatima Z. Brixi-Gormat

Volume 12, Issue 33, 2006

Page: [4313 - 4335] Pages: 23

DOI: 10.2174/138161206778792994

Price: $65

Abstract

Alzheimer disease (AD) is characterized by excessive deposition of amyloid β-peptides (Aβ peptides) in the form of senile plaques as well as neurofibrillary tangles (NFTs) in the brain. In the amyloidogenic pathway, the amyloid-β precursor protein (APP) is cleaved by β-secretase first, followed by γ-secretase cleavage producing therefore Aβ. This review summarizes the recent findings in the AD field and focuses on the different γ-secretase inhibitors that have been developed as a therapeutic approach toward AD.

Keywords: Alzheimer disease, amyloid βprecursor protein, amyloid β, γ-secretase, presenilins, γ-secretase inhibitors, nonsteroidal anti-inflammatory drugs


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy